Shardul Amarchand Mangaldas advised Eris Lifesciences on its acquisition of Dermatology and Nephrology branded formulations business units from Biocon Biologics
Shardul Amarchand Mangaldas advised Eris Lifesciences Limited (“Purchaser”) on its acquisition of business relating to commercialisation of branded generic dermatology and nephrology formulations and certain in-licensed products from Biocon Biologics Limited (“Seller”) The deal is approximately valued at INR 366 crores (~USD 43.9 million) and the date of closing the deal was 10 November 2023.
The deal was critical for Eris to mark its entry in the nephrology segment and to further strengthen its position in the dermatology segment of the market.
The transaction team was led by Nivedita Tiwari, Partner; Shailesh Singh, Principal Associate; and Anupama Singh, Senior Associate.
The employment law team was led by Pooja Ramchandani, Partner, and Suruchi Kumar, Principal Associate.
The IP law team was led by Apoorva Murali, Partner; and Neha Khanduri, Senior Associate.
The tax team was led by Amit Singhania, Partner; Ankita Bhasin, Counsel; Rahul Yadav, Counsel; and Mansie Jain, Associate.
The competition law team was led by Harman Singh Sandhu, Partner; Raveena Kumari Sethia, Senior Associate; and Abhishek Hazari, Associate.
Cyril Amarchand Mangaldas advised the seller.